These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 36135091)

  • 1. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
    Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
    Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
    Yu J; Du H; Ye X; Zhang L; Xiao H
    Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
    J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma.
    Hirono S; Iwadate Y; Higuchi Y; Serizawa T; Nagano O; Matsutani T; Saeki N
    J Neurooncol; 2015 Jun; 123(2):237-44. PubMed ID: 25911295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience.
    Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
    Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
    Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
    de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
    Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
    Reni M; Ferreri AJ
    Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature.
    Iwadate Y; Suganami A; Ikegami S; Shinozaki N; Matsutani T; Tamura Y; Saeki N; Yamanaka R
    J Neurooncol; 2014 Apr; 117(2):261-8. PubMed ID: 24488444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances and challenges in the treatment of primary central nervous system lymphoma.
    Yang H; Xun Y; Yang A; Liu F; You H
    J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A single-center, retrospective analysis of relapse and progression patterns of primary central nervous system lymphoma: can whole brain radiotherapy be replaced?].
    Qin Y; Liu R; Zhang X; Zhang W; Ren C; Wu D
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Apr; 43(4):499-506. PubMed ID: 37202184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Options for Recurrent Primary CNS Lymphoma.
    Kaulen LD; Baehring JM
    Curr Treat Options Oncol; 2022 Nov; 23(11):1548-1565. PubMed ID: 36205806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).
    Miyakita Y; Ohno M; Takahashi M; Muragaki Y; Katai H; Narita Y
    Jpn J Clin Oncol; 2017 Oct; 47(10):919-924. PubMed ID: 28981729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continued-Maintenance Therapy with High-dose Methotrexate Improves Overall Survival of Patients with Primary Central Nervous System Lymphoma.
    Nakajima K; Mizobuchi Y; Fujihara T; Azumi M; Takagi Y
    J Med Invest; 2021; 68(3.4):286-291. PubMed ID: 34759146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
    Kim N; Lim DH; Yoon SE; Kim SJ; Kim WS
    J Neurooncol; 2021 Sep; 154(2):207-217. PubMed ID: 34331673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
    Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
    Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis.
    Seidel S; Kowalski T; Nilius-Eliliwi V; Schroers R; Schlegel U
    Neurol Res Pract; 2023 Feb; 5(1):8. PubMed ID: 36814351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
    Suzuki Y; Imoto N; Ishihara S; Fujiwara S; Ito R; Sakai T; Yamamoto S; Sugiura I; Kurahashi S
    Intern Med; 2022 May; 61(9):1345-1352. PubMed ID: 34670884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.